Google Scholar citation report
Citations : 14978

Journal of Basic and Clinical Pharmacy received 14978 citations as per google scholar report

Indexed In

Chenjie He*
Department of Nanotechnology, Peking University, Beijing, China
*Correspondence: Chenjie He, Department of Nanotechnology, Peking University, Beijing, China, Email:

Received: 15-Nov-2023, Manuscript No. Jbclinphar-23-123969; Editor assigned: 17-Nov-2023, Pre QC No. Jbclinphar-23-123969 (PQ); Reviewed: 01-Dec-2023 QC No. Jbclinphar-23-123969; Revised: 08-Dec-2023, Manuscript No. Jbclinphar-23-123969 (R); Published: 15-Dec-2023

Citation: He C. Advantages of Direct Oral Anticoagulants and Therapy. J Basic Clin Pharma.2023,14(6):321.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact


Anticoagulation therapy is one treatment that has become both a lifesaver and a difficulty in the field of cardiovascular health. The advancement of medical knowledge has led to an increased comprehension of disorders affecting the cardiovascular system. Because they stop blood clots from developing, anticoagulants, also known as blood thinners, are essential in the treatment of a number of cardiovascular disorders. These problems can be fatal and include heart attacks and strokes. Anticoagulation treatment administration, however, requires an exact balance that presents a special type of difficulties for patients as well as healthcare professionals.

Anticoagulation therapy

Anticoagulation therapy primarily involves the use of medications that inhibit the blood’s ability to clot. This intervention is important for individuals with conditions such as atrial fibrillation, deep vein thrombosis and pulmonary embolism. By preventing the formation of blood clots, anticoagulants has a main role in reducing the risk of strokes and other thromboembolic events.

Commonly prescribed anticoagulants include warfarin, dabigatran, rivaroxaban and apixaban. Warfarin is a vitamin K antagonist that has a main role in the field, while Direct Oral Anticoagulants (DOACs) like dabigatran and rivaroxaban have gained popularity due to their predictable pharmacokinetics and fewer interactions with other medications.

Risks and benefits

While anticoagulation therapy has proven efficacy in preventing blood clots, its administration is a delicate balancing act. The therapy significantly reduces the risk of thromboembolic events that will increases the likelihood of bleeding complications. Striking the right balance between preventing clots by avoiding excessive bleeding is a task that needs a careful attention from both healthcare providers and patients.

Patients on anticoagulation therapy must be attached to a regular monitoring schedule to ensure that their blood clotting parameters, measured by the International Normalized Ratio (INR) for warfarin or other specific tests for DOACs, remain within the therapeutic range. Deviations from the optimal range can increase the risk of either clot formation or bleeding.

Individualized approach to anticoagulation

Anticoagulation treatment is extremely customized, which presents certain complications. Each patient responds differently to these medications by necessitating a personalized approach. Factors such as age, comorbidities, diet and concurrent medications can influence the efficacy and safety of anticoagulants.

The personalization of anticoagulant treatment has become even more sophisticated with the development of genetic testing. Genetic variations can impact an individual’s response to certain anticoagulants by guiding healthcare providers in customized treatment plans for optimal outcomes. Emergence of direct oral anticoagulants With the advent of DOACs, the field of anticoagulation treatment has gone through an important change in recent years. The pharmacokinetic profile of DOACs is more stable and they don't need to be analyzed regularly.


The development of anticoagulation treatment is evidence of the advancements in cardiovascular medicine. A careful and customized strategy is essential as we manage the currents of this complex therapeutic environments. Researchers and patients must work together to find a careful balance between reducing bleeding risks and preventing thromboembolic events.

The way anticoagulant treatment has changed throughout time from the warfarin of before to the modern DOACs reflects how quickly medical science is progressing. Anticoagulation care will change in the future due to continuous research, technology advancements and a patient centered approach by providing potential for better results and an improved quality of life for those with cardiovascular problems.